DBV Technologies S.A. - American Depositary Shares (DBVT)
NASDAQ:DBVT
Want to see DBVT full AI Analyst Report?
DBVT Stock Chart & Stats
$21.34
$0.34(9.80%)
At close: 4:00 PM EST
$21.34
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$7.53 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)228.84K
Market Cap
$1.05B
Enterprise Value$439.45M
Total Cash (Recent Filing)$229.20M
Total Debt (Recent Filing)$16.30M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Jul 29, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding59,212,300
10 Day Avg. Volume266,452
30 Day Avg. Volume228,841
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)9.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.67
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.37
Enterprise Value/Ebitda-2.76
Forecast
1Y Price Target
$40.97Price Target Upside91.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$4.36M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 VITESSE DataRobust Phase 3 results materially de-risk the lead program and underpin plans to pursue U.S. approval. If approved, Viaskin Peanut could secure early market share in pediatric peanut immunotherapy, creating a durable commercial and regulatory foundation for scaling the platform.
Low Financial LeverageA low debt load and improved equity provide a multimonth funding cushion and flexibility to pursue regulatory filings or partnerships. Reduced leverage lowers insolvency risk and preserves strategic options for financing or partnering through commercialization phases.
Differentiated EPIT PlatformThe Viaskin EPIT skin‑patch is a distinct, noninvasive delivery approach with tolerability demonstrated in a large trial. Platform scalability across allergens could create a sustainable competitive moat and multiple commercial indications if clinical and regulatory paths succeed.
Bears Say
No Revenue; Large Net LossesAbsent product revenue and significant recurring losses mean the company cannot self‑fund operations long term. Continued negative earnings erode equity, force reliance on external capital, and raise dilution and execution risk absent near‑term commercialization.
Sustained Cash BurnConsistent negative operating and free cash flow at material levels requires repeated financing or partnerships to sustain development and regulatory activities. Persistent cash burn constrains strategic flexibility and increases vulnerability to funding market conditions.
Structurally Negative Profitability MetricsNegative gross margins and deeply negative operating results indicate the business is far from self‑sustaining. Margin recovery depends on successful launch and scale, meaning profitability is contingent on execution risks across approval, manufacturing and commercialization.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies S.A. - American Depositary Shares’s price range in the past 12 months?
DBV Technologies S.A. - American Depositary Shares lowest stock price was $7.53 and its highest was $26.18 in the past 12 months.
What is DBV Technologies S.A. - American Depositary Shares’s market cap?
DBV Technologies S.A. - American Depositary Shares’s market cap is $1.05B.
When is DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date?
DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date is Jul 29, 2026 which is in 55 days.
How were DBV Technologies S.A. - American Depositary Shares’s earnings last quarter?
DBV Technologies S.A. - American Depositary Shares released its earnings results on Apr 30, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.024.
Is DBV Technologies S.A. - American Depositary Shares overvalued?
According to Wall Street analysts DBV Technologies S.A. - American Depositary Shares’s price is currently Undervalued.
Does DBV Technologies S.A. - American Depositary Shares pay dividends?
DBV Technologies S.A. - American Depositary Shares does not currently pay dividends.
What is DBV Technologies S.A. - American Depositary Shares’s EPS estimate?
DBV Technologies S.A. - American Depositary Shares’s EPS estimate is -0.11.
How many shares outstanding does DBV Technologies S.A. - American Depositary Shares have?
DBV Technologies S.A. - American Depositary Shares has 59,212,300 shares outstanding.
What happened to DBV Technologies S.A. - American Depositary Shares’s price movement after its last earnings report?
DBV Technologies S.A. - American Depositary Shares reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went down -5.381%.
Which hedge fund is a major shareholder of DBV Technologies S.A. - American Depositary Shares?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.97 (91.98% Upside)
$40.97 (91.98% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 14.8%
Last 30 Days ▼ 14.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.52%
12-Months-Change
Fundamentals
Return on Equity
-130.06%
Trailing 12-Months
Asset Growth
426.88%
Trailing 12-Months
Company Description
DBV Technologies S.A. - American Depositary Shares
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$40.97
▲(91.98% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
62.50% Insiders
2.33% Mutual Funds
32.54% Other Institutional Investors
2.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---